Immune cell army targets Hard-to-Treat cancers in new trial
NCT ID NCT07409766
First seen Feb 21, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This early-phase study tests a new treatment using specially engineered immune cells (CAR-Macrophages) to fight advanced solid tumors that have not responded to standard therapies. About 20 adults with specific tumor markers (like HER2 or PSMA) will receive the cells through an IV. The main goals are to check safety and find the best dose, while also looking for any signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.